ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

ClinicalTrials.gov ID: NCT00849290

Public ClinicalTrials.gov record NCT00849290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN OPEN LABEL, SINGLE ARM TRIAL OF IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED WITH PA2024 (APC8015F) FOR MEN WITH OBJECTIVE DISEASE PROGRESSION ON PROTOCOL D9902 PART B

Study identification

NCT ID
NCT00849290
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dendreon
Industry
Enrollment
113 participants

Conditions and interventions

Interventions

  • APC8015F Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2004
Primary completion
Dec 31, 2008
Completion
Mar 31, 2009
Last update posted
Nov 28, 2023

2004 – 2009

United States locations

U.S. sites
53
U.S. states
23
U.S. cities
43
Facility City State ZIP Site status
UCLA Los Angeles California
USC Keck School of Medicine Los Angeles California
Sutter Cancer Center Sacramento California
Kaiser Permanente Medical Group San Diego California
Sharp HealthCare San Diego California
UCSF Cancer Center San Francisco California
Helen F. Graham Cancer Center Newark Delaware
Lombardi Cancer Center Washington D.C. District of Columbia
Walter Reid Army Medical Center Washington D.C. District of Columbia
Miami Cancer Center Miami Florida
Hematology/Oncology Associates of the Treasure Coast Port Saint Lucie Florida
Georgia Urology, P.A. Atlanta Georgia
Midwest Prostate & Urology Health Center Chicago Illinois
Loyola University Maywood Illinois
Lutheran General Cancer Center Park Ridge Illinois
Indiana University Indianapolis Indiana
Myron I Murdock MD LLC Greenbelt Maryland
Dana-Farber Cancer Institute Boston Massachusetts
Lahey Clinic (Department of Urology) Burlington Massachusetts
University of Minnesota Minneapolis Minnesota
Mayo Clinic Rochester Minnesota
Nevada Cancer Institute Las Vegas Nevada
Hackensack University Medical Center Hackensack New Jersey
Associates in Urology, LLC West Orange New Jersey
Albany Regional Cancer Center Albany New York
The Urological Institute of Northeastern New York Albany New York
North Shore Hematology Oncology Associates East Setauket New York
New York Medical College Hawthorne New York
Beth Israel Cancer Center New York New York
Clinical Cancer Center New York New York
Mount Sinai School of Medicine New York New York
New York University New York New York
Staten Island Urological Research Staten Island New York
McKay Urology Charlotte North Carolina
Duke University Medical Center Durham North Carolina
University of Cincinnati Cincinnati Ohio
Cleveland Clinic Foundation Cleveland Ohio
EACRI Portland Oregon
Kaiser Permanente Medical Group Portland Oregon
Center for Urologic Care Bryn Mawr Pennsylvania
Jefferson Medical College Philadelphia Pennsylvania
Grand Strand Urology Myrtle Beach South Carolina
Mary Crowley Dallas Texas
Baylor College of Medicine Houston Texas
University of Utah Salt Lake City Utah
Urology of Virginia, PC Norfolk Virginia
Seattle Cancer Care Alliance Seattle Washington
Virginia Mason Medical Center Seattle Washington
Cancer Care Northwest Spokane Washington
Wenatchee Valley Medical Center Wenatchee Washington
University of Wisconsin, Madison Madison Wisconsin
University of Wisconsin Madison Wisconsin
St. Luke's Hospital Immunotherapy Program Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00849290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 28, 2023 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00849290 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →